GTC Drug Gets Orphan Status

Xconomy Boston — 

Framingham, MA-based GTC Biotherapeutics (NASDAQ: GTCB) announced that its lead drug candidate, ATryn, has received orphan-drug status as a treatment for patients with a rare hereditary clotting disease. The drug—a protein produced it the milk of genetically engineered goats—was fast-tracked by the FDA back in September; GTC plans to complete its filings for approval of the drug in the first half of 2008.